Who Paid My Doc
Tanveer Khan
Behavioral Neurology & Neuropsychiatry Conroe, TX Medical Doctor
NPI 1003343278 CMS profile 11426451
233 Sgt Ed Holcomb Blvd S, Conroe, TX 77304
General payments
$278
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Tanveer Khan of Conroe, TX is reported in the CMS Open Payments database as having received $278 across 5 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 45th percentile of Behavioral Neurology & Neuropsychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $26 | 1 | |
| 2024 | General | $24 | 1 | |
| 2022 | General | $229 | 3 |
Beside peers
- Tanveer Khan
- Behavioral Neurology & Neuropsychiatry median
- Middle half of Behavioral Neurology & Neuropsychiatry
- National median
In program year 2025, general payments to Tanveer Khan were reported at $26. Among 74 Behavioral Neurology & Neuropsychiatry profiles paid that year, the median was $152 and the middle half received between $53 and $1,035.
Show as a table
| Year | Tanveer Khan | Behavioral Neurology & Neuropsychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $211 | $86–$990 | $163 |
| 2020 | $0 | $270 | $54–$1,600 | $114 |
| 2021 | $0 | $267 | $60–$1,036 | $132 |
| 2022 | $229 | $255 | $69–$1,314 | $149 |
| 2023 | $0 | $170 | $50–$1,103 | $160 |
| 2024 | $24 | $173 | $39–$1,488 | $164 |
| 2025 | $26 | $152 | $53–$1,035 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 32 drugsPart D claims
1,198
Drug cost
$221,396
Branded share of claims
17.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ingrezza Valbenazine Tosylate | Brand | 12 | $96,258 | |
| Invega Sustenna Paliperidone Palmitate | Brand | 17 | $62,295 | |
| Lurasidone Hcl | Generic | 28 | $11,436 | |
| Paliperidone Er Paliperidone | Brand | 11 | $9,478 | |
| Divalproex Sodium Er Divalproex Sodium | Brand | 56 | $5,495 | |
| Quetiapine Fumarate | Generic | 146 | $4,281 | |
| Atomoxetine Hcl | Generic | 23 | $3,796 | |
| Olanzapine | Generic | 69 | $3,266 | |
| Oxcarbazepine | Generic | 32 | $2,797 | |
| Aripiprazole | Generic | 49 | $2,720 |
The 10 drugs with the highest cost, of 32 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 5 billing codesPaid by Medicare
$1,860
Medicare patients
38
Services billed
56
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 45% | |
| Depression | 39% | |
| Heart failure | 0% | |
| Ischemic heart disease | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
5 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Behavioral Neurology & Neuropsychiatry in Texas
Paul Schulz
Behavioral Neurology & Neuropsychiatry · Houston, TX
John Bertelson
Behavioral Neurology & Neuropsychiatry · Austin, TX
Hilary Butella
Behavioral Neurology & Neuropsychiatry · The Woodlands, TX
Garima Arora
Behavioral Neurology & Neuropsychiatry · Sugar Land, TX
Gabriel De Erausquin
Behavioral Neurology & Neuropsychiatry · San Antonio, TX
David Hunter
Behavioral Neurology & Neuropsychiatry · Houston, TX
Related records
Behavioral Neurology & Neuropsychiatry in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Behavioral Neurology & Neuropsychiatry
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.